Cargando…

Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies

SIMPLE SUMMARY: Glioblastoma is an incurable disease, demanding new therapeutic approaches. Our preclinical studies proved that the antidiabetic drug metformin could induce the differentiation of stem-like glioma-initiating cells and suppress tumor formation through AMPK-FOXO3 activation, suggesting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohno, Makoto, Kitanaka, Chifumi, Miyakita, Yasuji, Tanaka, Shota, Sonoda, Yukihiko, Mishima, Kazuhiko, Ishikawa, Eiichi, Takahashi, Masamichi, Yanagisawa, Shunsuke, Ohashi, Ken, Nagane, Motoo, Narita, Yoshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454846/ https://www.ncbi.nlm.nih.gov/pubmed/36077758 http://dx.doi.org/10.3390/cancers14174222

Ejemplares similares

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

NQPC-10 IMPACT OF HEALTH-RELATED QOL (HRQOL) IN THE FIRST SIX MONTHS AFTER SURGERY ON LONG-TERM POSTOPERATIVE GENERAL HEALTH STATUS IN GLIOMA PATIENTS
por: Kugasawa, Kazuha, et al.
Publicado: (2022)

ML-12 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT) FOR THE PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Miyakita, Yasuji, et al.
Publicado: (2022)

MET-10 A SINGLE CENTER RETROSPECTIVE ANALYSIS OF AWAKE CRANIOTOMY FOR METASTATIC BRAIN TUMOR
por: Yanagisawa, Shunsuke, et al.
Publicado: (2022)

Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence
por: Kawauchi, Daisuke, et al.
Publicado: (2023)

NQPC-13 THE EFFICACY OF RAVEN’S COLORED PROGRESSIVE MATRICES FOR PATIENTS WITH BRAIN TUMOR
por: Yahiro, Sachiko, et al.
Publicado: (2019)

STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
por: Ohno, Makoto, et al.
Publicado: (2021)

Early Diagnosis and Surgical Intervention Within 3 Weeks From Symptom Onset Are Associated With Prolonged Survival of Patients With Glioblastoma
por: Kawauchi, Daisuke, et al.
Publicado: (2022)

Dose-dense Temozolomide: Is It Still Promising?
por: NAGANE, Motoo
Publicado: (2015)

ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
por: Kikuchi, Miyu, et al.
Publicado: (2021)

NQPC-14 COMPARISON OF QOL SCALES IN PATIENTS WITH BRAIN TUMORS
por: Satomi, Natsuko Tsushita, et al.
Publicado: (2019)

SS-1 Therapeutic challenges for glioblastoma: Temozolomide and its issues?
por: Nagane, Motoo
Publicado: (2020)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma
por: Ohno, Makoto, et al.
Publicado: (2022)

NQPC-10 END-OF-LIFE PHASE OF GLIOBLASTOMA
por: Omura, Tomoko, et al.
Publicado: (2019)

COT-04 FAMILY SUPPORT FOR PATIENTS WITH PRIMARY MALIGNANT BRAIN TUMORS BY PATIENT SUPPORT GROUP IN NATIONAL CANCER CENTER
por: Horikawa, Mayumi, et al.
Publicado: (2019)

COT-23 INITIAL EXPERIENCE OF TREATMENT FOR GLIOBLASTOMA BY NOVO-TTF
por: Omura, Takaki, et al.
Publicado: (2019)

Combination of asleep and awake craniotomy as a novel strategy for resection in patients with butterfly glioblastoma: Two case reports
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

MPC-11 IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETRY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM
por: Ohno, Makoto, et al.
Publicado: (2019)

COT-15 LITERATURE REVIEW ON THE DECISION MAKING OF THE BRAIN TUMOR PATIENT
por: Kishi, Tatsuya, et al.
Publicado: (2019)

HGG-39. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RADIATION-INDUCED GLIOMA
por: Ohno, Makoto, et al.
Publicado: (2020)

PEDT-12 NATIONWIDE LANDSCAPE OF GENOMIC ANALYSIS OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS
por: Watanabe, Yuko, et al.
Publicado: (2022)

Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study
por: Aoki, Tomokazu, et al.
Publicado: (2021)

RT-5 Boron Neutron Capture Therapy has extended progression-free survival about recurrent malignant peripheral nerve sheath tumor - A case report
por: Watanabe, Yuko, et al.
Publicado: (2021)

INTRAVASCULAR LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM PRESENTING AS MULTIPLE CEREBRAL INFARCTIONS
por: MOMOTA, HIROYUKI, et al.
Publicado: (2012)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

A rare case of brain metastasis from poorly differentiated small bowel adenocarcinoma
por: Yamazawa, Erika, et al.
Publicado: (2019)

Clinical presentation of anaplastic large-cell lymphoma in the central nervous system
por: NOMURA, MASASHI, et al.
Publicado: (2013)

JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma
por: Wakabayashi, Toshihiko, et al.
Publicado: (2018)

ML-05 One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
por: Mishima, Kazuhiko, et al.
Publicado: (2020)

Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib
por: Arakawa, Yoshiki, et al.
Publicado: (2023)

A retrospective analysis of the prognosis of Japanese patients with sarcoma brain metastasis
por: Toda, Yu, et al.
Publicado: (2023)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo
por: Mitobe, Yuta, et al.
Publicado: (2023)

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
por: Narita, Yoshitaka, et al.
Publicado: (2020)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo
por: Nitta, Yusuke, et al.
Publicado: (2016)

“Comet tail sign”: A pitfall of post-gadolinium magnetic resonance imaging findings for metastatic brain tumors
por: Mitsuya, Koichi, et al.
Publicado: (2016)

Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma
por: Ohno, Makoto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_st5iiicio69b69hb55gq9vjljr